These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19888518)

  • 1. Heparins: process-related physico-chemical and compositional characteristics, fingerprints and impurities.
    Liverani L; Mascellani G; Spelta F
    Thromb Haemost; 2009 Nov; 102(5):846-53. PubMed ID: 19888518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an ion-exchange chromatography method for heparin and its impurities in heparin products.
    Thiangthum S; Vander Heyden Y; Buchberger W; Viaene J; Prutthiwanasan B; Suntornsuk L
    J Sep Sci; 2014 Nov; 37(22):3195-204. PubMed ID: 25146711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.
    Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U
    Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of pharmaceutical heparins and potential contaminants using (1)H-NMR and PAGE.
    Zhang Z; Li B; Suwan J; Zhang F; Wang Z; Liu H; Mulloy B; Linhardt RJ
    J Pharm Sci; 2009 Nov; 98(11):4017-26. PubMed ID: 19642166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2011 Jan; 54(2):337-44. PubMed ID: 20934294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-dimensional cellulose acetate plate electrophoresis--a feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin.
    Domanig R; Jöbstl W; Gruber S; Freudemann T
    J Pharm Biomed Anal; 2009 Jan; 49(1):151-5. PubMed ID: 19062213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Source-induced fragmentation of heparin, heparan, and galactosaminoglycans and application.
    Hu P; Fang L; Chess EK
    Anal Chem; 2009 Mar; 81(6):2332-43. PubMed ID: 19228018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of Oversulphated Chondroitin Sulphate and Dermatan Sulphate in unfractionated heparin by (1)H-NMR - Collaborative study for quantification and analytical determination of LoD.
    McEwen I; Mulloy B; Hellwig E; Kozerski L; Beyer T; Holzgrabe U; Wanko R; Spieser JM; Rodomonte A
    Pharmeuropa Bio; 2008 Dec; 2008(1):31-9. PubMed ID: 19220979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractionation of heparin, dermatan sulfate, and chondroitin sulfate by sequential precipitation: a method to purify a single glycosaminoglycan species from a mixture.
    Volpi N
    Anal Biochem; 1994 May; 218(2):382-91. PubMed ID: 8074297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of galactosamine impurities in heparin sodium using fluorescent labeling and conventional high-performance liquid chromatography.
    Itoh S; Hiruta Y; Hashii N; Fujita N; Natsuga T; Hattori T; Bando A; Sekimoto Y; Miyata K; Namekawa H; Mabuchi K; Sakai T; Shimahashi H; Kawai K; Yoden H; Koyama S; Herr SO; Natsuka S; Yamaguchi T; Kawasaki N
    Biologicals; 2013 Nov; 41(6):355-63. PubMed ID: 23827519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
    Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
    Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in quantitative polymerase chain reaction applied to control the quality of heparins.
    Auguste C; Dereux S; Martinez C; Anger P
    Anal Bioanal Chem; 2011 Jan; 399(2):747-55. PubMed ID: 20931175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of dermatan sulfate and chondroitin sulfate as related substances in heparin by capillary electrophoresis.
    Bendazzoli C; Liverani L; Spelta F; Prandi M; Fiori J; Gotti R
    J Pharm Biomed Anal; 2010 Dec; 53(5):1193-200. PubMed ID: 20674212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and purity test of heparin by NMR - a summary of two years' experience at the Medical Products Agency.
    McEwen I; Amini A; Olofsson IM
    Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):65-72. PubMed ID: 20223191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
    Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.